INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC

Core Insights - Holzer & Holzer, LLC is investigating UroGen Pharma Ltd. for potential compliance issues with federal securities laws following FDA comments on the company's clinical trial results [1] - The FDA indicated that the lack of a concurrent control arm in the ENVISION trial makes it difficult to interpret the primary endpoints of complete response (CR) and duration of response (DOR) [1] - UroGen's stock price experienced a decline after the FDA's statement regarding the investigational product UGN-102 [1] Company Overview - UroGen Pharma Ltd. is a publicly traded company on NASDAQ under the ticker URGN [1] - The company is involved in developing treatments for urological diseases, with a focus on innovative therapies [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]